News

Aurora Spine Corporation Schedules Conference Call to Update Investors and Discuss Second Quarter Fiscal Year 2023 Financial Results

CARLSBAD, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),…

1 year ago

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations…

1 year ago

ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment

More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204…

1 year ago

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein…

1 year ago

Genelux Corporation Announces New Chief Financial Officer

WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced…

1 year ago

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model

Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and…

1 year ago

Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for…

1 year ago

CLS Americas and Focalyx Co-Marketing Agreement for Image-Guided Focal Laser Ablation of Prostate Tumors Using TRANBERG and Focalyx Fusion Systems

Minimally Invasive, Outpatient Treatment Designed for Quick Recovery and Low Risk of Unwanted ED and UI Side EffectsIRVINE, Calif. and…

1 year ago

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights…

1 year ago